Johnson & Johnson (J&J, NYSE: JNJ) Innovative Medicine China has recently made two major appointments to its leadership team. The company has appointed a new general manager and a new vice president.
New General Manager
As of March 1, 2025, Mr. Chen Jian will take on the role of head of business operations and innovation diversification, as well as the general manager of Johnson & Johnson Pharmaceuticals Co., Ltd. In his new position, Mr. Chen will be responsible for forming and leading a team to comprehensively develop and implement J&J’s innovative pharmaceutical winning strategy in China. His focus will be on maximizing existing and future market access opportunities for innovative products, building an ecosystem for government affairs and key disease areas, expanding diversified growth, and promoting and establishing innovative business models.
New Vice President
Meanwhile, Sévan Kaloustian has been appointed as the vice president and head of the oncology business unit of Johnson & Johnson Innovative Medicine China. He will report to Ms. Cherry Huang, president of Johnson & Johnson Innovative Medicine China. Sévan Kaloustian holds a PhD in pharmacology and a Master’s degree in pharmacoeconomics from the University of Montreal in Canada. He previously served as the managing director for the Jordan, Egypt, and North Africa region.-Fineline Info & Tech
